Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | TYMS | P04818 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316941 | 0.91 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFRTYMS | |
| SCHEMBL24316489 | 0.84 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4CYP2A6HSP90AA1 | |
| SCHEMBL25038158 | 0.81 | PDK2 (0.39) | SLC6A3SLC6A4CYP2A6HSD11B1PDK2 | |
| SCHEMBL25035922 | 0.81 | TDP2 (0.33) | HSP90AA1HSP90AB1CYP1A2CYP1B1 | |
| SCHEMBL24618091 | 0.80 | HSD11B1 (0.36) | HSD11B1PDK2 | |
| SCHEMBL24316936 | 0.80 | ALOX5 (0.30) | — | |
| SCHEMBL25035875 | 0.80 | CYP2A6 (0.37) | SLC6A3SLC6A2SLC6A4DHFRTYMS | |
| SCHEMBL24728354 | 0.79 | PDK2 (0.49) | HSD11B1PDK2CYP1A2 | |
| SCHEMBL22797179 | 0.79 | PDK2 (0.49) | HSD11B1PDK2CYP1A2 | |
| SCHEMBL24316406 | 0.79 | CYP2A6 (0.39) | SLC6A3SLC6A2SLC6A4DHFRTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2022068292-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | 陕西莱特光电材料股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | OR51E2, SQLE, ODC1 | SLC6A3 558/4885SLC6A2 638/4885SLC6A4 1667/4885 |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | NOD1, NFE2L2, NOTCH1 | SLC6A3 4182/4885SLC6A2 2701/4885SLC6A4 3710/4885 |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | LEF1, OCIAD1, OR10J3 | SLC6A3 3896/4885SLC6A2 3345/4885SLC6A4 3717/4885 |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | NOD1, NFE2L2, NOTCH1 | SLC6A3 4182/4885SLC6A2 2701/4885SLC6A4 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.